Bayer's Prescription Drugs business unit focuses on treatment areas such as cardiology, oncology, gynecology, hematology and ophthalmology. With innovative prescription drug products, Bayer strives to help patients achieve the desired results while meeting the ever-increasing needs of doctors and medical payment agencies. Bayer's Prescription Drugs Division is headquartered in Beijing, China, and has factories in Beijing and Guangzhou.
From 1995 to 1997, Bayer built a pharmaceutical production and packaging plant in Beijing to manufacture solid and semi-solid products. In order to meet the growing demand in the Chinese market, the company invested heavily to expand the production base in Beijing. After several expansions, the production capacity of the production base in Beijing has been greatly increased, and production equipment with advanced technology has been assembled. In 2011, the Beijing factory obtained the GMP certificate issued by the Beijing Drug Administration.
In order to meet the growing demand for products in the Chinese market, Bayer invested 100 million euros to increase the production capacity of the Beijing plant on a large scale. The capacity expansion plan aims to ensure a stable supply of high-quality products to meet the needs of Chinese patients for Bayer prescription drug products for cardiovascular disease and diabetes. The expansion project includes the expansion of logistics logistics areas for fully automated material handling, analysis laboratories, and high-speed packaging production lines.
At the same time, Bayer has launched long-term strategic cooperation with world-renowned academic institutions to promote cutting-edge breakthroughs in basic research and drug discovery. In China, Bayer continues to deepen its strategic partnerships with other well-known local academic institutions such as Tsinghua University, Peking University, and the Shanghai Institute of Organic Chemistry of the Chinese Academy of Sciences. In March 2018, the cooperation between Bayer and Tsinghua University entered its tenth year, and the two parties renewed the strategic R & D cooperation agreement. The two parties will continue to cooperate in the field of innovative drug research and development in the next three years.
Bayer has always focused on China's county-level medical service capabilities and has continued to invest in this area. In the past ten years, the "Go West" health talent training program has trained more than 45,000 physicians and health managers in 26 provinces across the country. In 2018, the "Go West" project officially entered the third five-year phase, and it is planned to expand to 31 provinces, cities and regions across the country to increase coverage outside the Midwest.
In addition, the imaging diagnostics business of the Bayer Prescription Drugs Division provides advanced diagnostic imaging solutions worldwide. In the field of imaging diagnostics, Bayer's products in China include contrast agents, injection devices and information processing solutions. In China, Bayer brings advanced science and technology to experts and academic organizations in the field of imaging diagnosis through a strong training system. In addition to the traditional strengths of Uvaxant in the CT field and Medrida syringes, Bayer is also regarded as an advanced company in the MR product portfolio with the use of Carrex for systemic imaging and Pulmox for liver imaging.